1. Translational models of primary and secondary drug resistance in invasive thyroid cancer.
2. Role of stem cell-like pericytes in resistance to BRAFV600E inhibitors and tyrosine kinase inhibitors (TKI).
3. Role of a newly-identified thyroid-specific lincRNA in thyroid cancer.
02/15/2021 - 5:00pm to 6:00pm CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Carmelo Nucera, M.D., Ph.D.